On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyﾒs Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate.

The studyﾒs primary objective was to examine the safety and reactogenicity of two-doses of the vaccine. Secondary objectives include immunogenicity, duration of immune response and occurrence of symptomatic COVID-19.